• Marco Sassi, Edvin Zekaj, Alessandra Grotta, Alberto Pollini, Armando Pellanda, Massimo Borroni, Claudio Pacchetti, Claudia Menghetti, Mauro Porta, and Domenico Servello.
• Functional Neurosurgical Unit, IRCCS Galeazzi, Milan, Italy; Department of Statistics, University of Milano-Bicocca, Milan, Italy; Department of Neurology, IRCCS C. Mondino Institute of Neurology Foundation, University of Pavia, Pavia, Italy.
• Neuromodulation. 2013 Sep 1;16(5):401-6; discussion 406.

ObjectiveEvaluation of safety and efficacy of dexmedetomidine in deep brain stimulation (DBS) surgery.Materials And MethodsA cohort of 23 patients, candidates for DBS for Parkinson's disease, Tourette syndrome, or obsessive-compulsive disorder, was randomized in two groups: dexmedetomidine group and control group. Standard anesthesiologic parameters were recorded and analyzed, together with the need for other medications. A ten-degree scale (visual analog scale) assessing patient discomfort during DBS also was recorded at the end of surgery.ResultsThe results demonstrated good stability of intraoperative monitoring: no respiratory depression and good overall cooperation with the neurologist, while no side-effects were recorded.ConclusionsOur conclusion is that dexmedetomidine should be considered as a valuable option for sedation in poorly collaborating patients undergoing DBS surgery.© 2012 International Neuromodulation Society.

28 keywords...

hide…